Olsen, E. A., Duvic, M., Breneman, D., Pacheco, T. R., Parker, S., Vonderheid, E. C., … Geskin, L. J. (2008). Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL). Journal of Clinical Oncology, 26(15_suppl), 14588–14588. https://doi.org/10.1200/jco.2008.26.15_suppl.14588

Olsen, E. A., M. Duvic, D. Breneman, T. R. Pacheco, S. Parker, E. C. Vonderheid, J. L. Ricker, S. Rizvi, K. Boileau, and L. J. Geskin. “Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 14588–14588. https://doi.org/10.1200/jco.2008.26.15_suppl.14588.

Olsen EA, Duvic M, Breneman D, Pacheco TR, Parker S, Vonderheid EC, et al. Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):14588–14588.

Olsen, E. A., et al. “Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL).” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 14588–14588. Crossref, doi:10.1200/jco.2008.26.15_suppl.14588.

Olsen EA, Duvic M, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Ricker JL, Rizvi S, Boileau K, Geskin LJ. Vorinostat provides prolonged safety and clinical benefit to patients with advanced cutaneous t-cell lymphoma (CTCL). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):14588–14588.